An allosteric modulator of the α7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 1, 2007, Pages 294-307

  Timmermann, Daniel B ^a   Grønlien, Jens Halvard ^c   Kohlhaas, Kathy L ^c   Nielsen, Elsebet Ø ^a   Dam, Eva ^a   Jørgensen, Tino D ^a   Ahring, Philip K ^b   Peters, Dan ^a   Holst, Dorte ^a   Chrsitensen, Jeppe K ^a   Malysz, John ^c   Briggs, Clark A ^c   Gopalakrishnan, Murali ^c   Olsen, Gunnar M ^a  

^a NEUROSEARCH A S   (Denmark)

^b Neurosearch A/S Norway   (Norway)

^c ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 CHLORO 2 HYDROXYPHENYL) 3 (2 CHLORO 5 TRIFLUOROMETHYLPHENYL)UREA; ACETYLCHOLINE; BUNGAROTOXIN RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; NS 1738; RADIOLIGAND; SCOPOLAMINE; UNCLASSIFIED DRUG; 1-(5-CHLORO-2-HYDROXYPHENYL)-3-(2-CHLORO-5-TRIFLUOROMETHYLPHENYL)UREA; ALPHA-BUNGAROTOXIN RECEPTOR; CARBANILAMIDE DERIVATIVE; NICOTINIC RECEPTOR;

ALLOSTERISM; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; ELECTROPHYSIOLOGY; GENETIC TRANSFECTION; HIPPOCAMPUS; IN VIVO STUDY; LEARNING; LIGAND BINDING; MALE; MAMMAL CELL; MAZE TEST; MEMORY DISORDER; NEWBORN; NONHUMAN; OOCYTE; PATCH CLAMP; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; SCHIZOPHRENIA; SOCIAL BEHAVIOR; XENOPUS LAEVIS; ACTION POTENTIAL; ANIMAL; BLOOD; COGNITION; CYTOLOGY; DRUG EFFECT; HUMAN; METABOLISM; MOLECULAR CLONING; NERVE CELL; SHORT TERM MEMORY; SPRAGUE DAWLEY RAT; TUMOR CELL LINE; WISTAR RAT;

ACTION POTENTIALS; ALLOSTERIC REGULATION; ANIMALS; CELL LINE, TUMOR; CHOLINERGIC AGENTS; CLONING, MOLECULAR; COGNITION; HIPPOCAMPUS; HUMANS; MALE; MAZE LEARNING; MEMORY, SHORT-TERM; NEURONS; OOCYTES; PATCH-CLAMP TECHNIQUES; PHENYLUREA COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, NICOTINIC; XENOPUS LAEVIS;

EID: 34548689531     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.120436     Document Type: Article

References (40)

1. Alkondon M and Albuquerque EX (1993) Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. I. Pharmacological and functional evidence for distinct structural subtypes. J Pharmacol Exp Ther 265:1455-1473.
2. Arendash GW, Sengstock GJ, Sanberg PR, and Kem WR (1995) Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res 674:252-259.
3. Boess FG, De VJ, Erb C, Flessner T, Hendrix M, Luithle J, Methfessel C, Riedl B, Schnizler K, van der Staay FJ, et al. (2007) The novel α7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2. 2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents. J Pharmacol Exp Ther 321:716-725.
4. Briggs CA, Anderson DJ, Brioni JD, Buccafusco JJ, Buckley MJ, Campbell JE, Decker MW, Donnelly-Roberts D, Elliott RL, Gopalakrishnan M, et al. (1997) Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol Biochem Behav 57:231-241.
5. Briggs CA and McKenna DG (1998) Activation and inhibition of the human alpha7 nicotinic acetylcholine receptor by agonists. Neuropharmacology 37:1095-1102.
6. Briggs CA, McKenna DG, and Piattoni-Kaplan M (1995) Human alpha 7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacology 34:583-590.
7. Burghaus L, Schutz U, Krempel U, de Vos RA, Jansen Steur EN, Wevers A, Lindstrom J, and Schroder H (2000) Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res Mol Brain Res 76:385-388.
8. Chimienti F, Hogg RC, Plantard L, Lehmann C, Brakch N, Fischer J, Huber M, Bertrand D, and Hohl D (2003) Identification of SLURP-1 as an epidermal neuromodulator explains the clinical phenotype of Mal de Meleda. Hum Mol Genet 12:3017-3024.
9. Conroy WG, Liu QS, Nai Q, Margiotta JF, and Berg DK (2003) Potentiation of α7-containing nicotinic acetylcholine receptors by select albumins. Mol Pharmacol 63:419-428.
10. Curzon P, Anderson DJ, Nikkel AL, Fox GB, Gopalakrishnan M, Decker MW, and Bitner RS (2006) Antisense knockdown of the rat alpha7 nicotinic acetylcholine receptor produces spatial memory impairment. Neurosci Lett 410:15-19.
11. Dajas-Bailador F and Wonnacott S (2004) Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol Sci 25:317-324.
12. Felix R and Levin ED (1997) Nicotinic antagonist administration into the ventral hippocampus and spatial working memory in rats. Neuroscience 81:1009-1017.
13. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, et al. (1997) Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A 94:587-592.
14. Freedman R, Hall M, Adler LE, and Leonard S (1995) Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38:22-33.
15. Greenfield SA, Day T, Mann EO, and Bermudez I (2004) A novel peptide modulates alpha7 nicotinic receptor responses: implications for a possible trophic-toxic mechanism within the brain. J Neurochem 90:325-331.
16. Hajós M, Hurst RS, Hoffmann WE, Krause M, Wall TM, Higdon NR, and Groppi VE (2005) The selective α7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4- chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther 312:1213-1222.
17. Hurst RS, Hajós M, Raggenbass M, Wall TM, Higdon NR, Lawson JA, Rutherford-Root KL, Berkenpas MB, Hoffmann WE, Piotrowski DW, et al. (2005) A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci 25:4396-4405.
18. Kitagawa H, Takenouchi T, Azuma R, Wesnes KA, Kramer WG, Clody DE, and Burnett AL (2003) Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 28:542-551.
19. Krause RM, Buisson B, Bertrand S, Corringer PJ, Galzi JL, Changeux JP, and Bertrand D (1998) Ivermectin: a positive allosteric effector of the α7 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 53:283-294.
20. Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M, Drebing C, Berger R, Venn D, Sirota P, et al. (2002) Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 59:1085-1096.
21. Levin ED and Simon BB (1998) Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 138:217-230.
22. Lewis TM, Harkness PC, Sivilotti LG, Colquhoun D, and Millar NS (1997) The ion channel properties of a rat recombinant neuronal nicotinic receptor are dependent on the host cell type. J Physiol 505:299-306.
23. Lindstrom J (2000) The structures of neuronal nicotinic receptors, in Neuronal Nicotinic Receptors (Clementi F, Fornusari D, and Gotti C eds) pp 101-162, Springer Verlag, Berlin.
24. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
25. A receptor modulators. Proc Natl Acad Sci U S A 104:8059-8064.
26. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, et al. (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63:630-638.
27. Patel S and Tariot PN (1991) Pharmacologic models of Alzheimer's disease. Psychiatr Clin North Am 14:287-308.
28. Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, Gueudet C, Voltz C, Steinberg R, Stemmelin J, et al. (2007) SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) Efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 32:17-34.
29. Quick MW and Lester RA (2002) Desensitization of neuronal nicotinic receptors. J Neurobiol 53:457-478.
30. Quik M, Choremis J, Komourian J, Lukas RJ, and Puchacz E (1996) Similarity between rat brain nicotinic alpha-bungarotoxin receptors and stably expressed alpha-bungarotoxin binding sites. J Neurochem 67:145-154.
31. Rezvani AH and Levin ED (2001) Cognitive effects of nicotine. Biol Psychiatry 49:258-267.
32. Sine SM (1988) Functional properties of human skeletal muscle acetylcholine receptors expressed by the TE671 cell line. J Biol Chem 263:18052-18062.
33. Somnier FE (1994) Anti-acetylcholine receptor (AChR) antibodies measurement in myasthenia gravis: the use of cell line TE671 as a source of AChR antigen. J Neuroimmunol 51:63-68.
34. Stevens KE, Freedman R, Collins AC, Hall M, Leonard S, Marks MJ, and Rose GM (1996) Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacology 15:152-162.
35. Stevens KE, Kem WR, Mahnir VM, and Freedman R (1998) Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology 136:320-327.
36. Trumbull JD, Maslana ES, McKenna DG, Nemcek TA, Niforatos W, Pan JY, Parihar AS, Shieh CC, Wilkins JA, Briggs CA, et al. (2003) High throughput electrophysiology using a fully automated, multiplexed recording system. Receptors Channels 9:19-28.
37. Van Kampen M, Selbach K, Schneider R, Schiegel E, Boess F, and Schreiber R (2004) AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors. Psychopharmacology 172:375-383.
38. Virginio C, Giacometti A, Aldegheri L, Rimland JM, and Terstappen GC (2002) Pharmacological properties of rat alpha 7 nicotinic receptors expressed in native and recombinant cell systems. Eur J Pharmacol 445:153-161.
39. Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, Olson KL, Jacobsen EJ, Wolfe ML, Groppi VE, et al. (2006) Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c] pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure-activity relationship. J Med Chem 49:4425-4436.
40. Zwart R, De Filippi G, Broad LM, McPhie GI, Pearson KH, Baldwinson T, and Sher E (2002) 5-Hydroxyindole potentiates human alpha 7 nicotinic receptor-mediated responses and enhances acetylcholine-induced glutamate release in cerebellar slices. Neuropharmacology 43:374-384.